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ER-alpha and ER-beta genes have been proven to play a significant role in breast cancer. Epidemiologic studies have 
revealed that age-incidence patterns of breast cancer in Middle East differ from those in the Western countries. Two 
selected coding regions in the ER-β gene (exons 3 and 7) were scanned in Iranian women with breast cancer (150) and 
in healthy individuals (147). PCR single-strand conformation polymorphism was performed. A site of silent single 
nucleotide polymorphism was found only on exon 7. The SNP was found only in breast cancer patients (5.7%) (χ2 = 
17.122, P = 0.01). Codon 392 (C1176G) of allele 1 was found to have direct association with the occurrence of lymph 
node metastasis. Our data suggest that ER-β polymorphism in exon 7 codon 392 (C1176G) is correlated with various 
aspects of breast cancer and lymph node metastasis in our group of patients.
Introduction
Breast cancer is the most prevalent cancer among women
in most parts of the world, including Iran. Geographical
variations in incidence and mortality rates of breast can-
cer suggest that the known risk factors for breast cancer
may vary in different parts of the world and that environ-
mental factors may be of greater importance than genetic
factors [1]. For instance, in Iran it has been shown that,
even after adjusting for age, young women are at rela-
tively higher risk for developing breast cancer than are
their Western counterparts [2,3].
It is known that breast cancer typically arises in luminal
epithelial cells of the mammary gland [4,5]. These cells
contain estrogen receptors (ERs), which respond to ovar-
ian estrogen in normal mammary gland development.
How estrogens stimulate cell growth is not fully under-
s t ood ,  b u t  i t  i s  k n o w n  t h a t  e s t r o g e n  a c t i va t i o n  o f  E Rs
results in transcription of various genes that are involved
in cellular proliferation
Only a small fraction (< 5%) of women diagnosed with
breast cancer have a clear hereditary predisposition [6-8],
and of these, about one half have predisposing mutations
in BRCA1, BRCA2, PTEN, TP53, or other known cancer
predisposing genes. However, twin studies indicate that
the heritability of breast cancer is about 30% [9], suggest-
ing that genes other than the well-mapped regions act as
modifiers of breast cancer risk. Although it is likely that
low penetrance as well as high penetrance genes may be
involved in the etiology, it remains unclear which
genomic regions and which biochemical functions or sig-
nal transduction pathways account for the additional her-
itability of breast cancer incidence or progression.
Epidemiologic evidence suggests that estrogen plays a
crucial role in most breast cancers in women who have
both early menarche and late menopause. Obesity is also
associated with breast cancer risk; estrogen synthesis in
adipose tissue is proposed to account for this increase in
risk. There is data on the involvement of estrogen recep-
tor in the molecular processes implicated in the rise of
breast cancer incidence [10-16].
ER-α polymorphic variants have been associated with
breast cancer risk [17-25] in Caucasians. Furthermore,
ER-α has been studied extensively, but supporting evi-
dence is required for proving the involvement of ER-β in
breast cancer [26-33]. Currently, the literature contains
sparse information regarding ER-β gene expression,
mutation frequency, and allelic variation in breast cancer.
Thus, the present study aimed to identify candidate ste-
roid hormone receptor gene variants in randomly
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selected regions (exon 3 and exon 7) of the ER-β gene that
might be associated with risk of breast cancer . It is our
long-term objective to establish a genetic polymorphism
database for the ER-β encoding regions of the Iranian
(Asian-Caucasian) genome, and to test for any correlation
between ER-β polymorphism and various clinically
observable features of breast cancer in Iranian women.
Methods
Study population
A case-control study was conducted from April 2004 to
January 2008 in Tehran, Iran. The breast cancer patients
(n = 150; mean age 47.49 ± 11.43 years) were newly diag-
nosed and mostly living in Tehran. They were entered
into the study if they had a confirmed pathological breast
cancer diagnosis at the Imam Khomeini Hospital Com-
plex (a large teaching and general hospital in the central
district of Tehran) and were referred to the several clinics
of the Cancer Institute of the hospital. The control group
(n  = 147; median age 40.75 ± 10.54 years) included
healthy women neither with any history of breast cancer
nor any other neoplastic diseases, and none of their rela-
tives had a history of breast cancer diagnosed at the same
clinics [34]. Women with hysterectomy and artificial
menopause, or women exposed to any kind of radiation
and chemotherapy in their lifetime were excluded from
the study. All participants in our study provided written
informed consent to participate before entering the pres-
ent study.
Demographical and risk factor data were collected
using a short structured questionnaire, including infor-
mation on age, weight, height, race, religion, marital sta-
tus, number of pregnancies and children, age at first child
birth, average lactation term, family history of breast can-
cer (first-degree relatives), age at menarche, age at mar-
riage, menopausal status, and age at menopause, ABO
and Rhesus blood groups, race, age at onset, lymph node
metastases, cancer stage at the time of testing and ER
expression in breast cancer tissue. A protocol to collect
and store blood samples for future genomic tests had
been approved by the institutional review board. Periph-
eral blood was collected and genotyping analysis was per-
formed.
Screening for ER-β variants by single strand conformation 
polymorphism analysis
In order to identify any change in the two selected exons
(exons 3 and exon 7) of ER-β, PCR and SSCP was per-
formed. Genomic DNA was extracted from blood leuko-
cytes using the DNG™-Plus extraction kit (Cinnagen Inc,
Tehran, Iran) in accordance with the manufacturer's
instructions. Specific set of primers for ER-β gene exons 3
and 7 were designed by primer3 (v. 0.4.0) software (Table
1).
PCR was performed through 30 cycles with the follow-
ing steps: denaturation 30 sec at 95°C, annealing 30 sec at
58°C and elongation 40 seconds at 72°C. The SSCP was
carried out on 12% polyacrylamide gel (29:1 Acrylamide/
Bisacrylamide), with 200 V, for 20 h at 16°C. After elec-
trophoresis, silver nitrate staining was used for visualiz-
ing the bands. To identify and confirm the exhibited
irregular pattern in SSCP, PCR samples demonstrating
varying band shift patterns as the result of first sequenc-
ing with forward primer, were re-purified on agarose gel
using a DNA Extraction Kit (Fermentas # K0153, Ger-
many) and directly sequenced by big dye Terminator V3.1
Cycle Sequencing kit protocol, (Applied Biosystem Kit,
Microgen Co., USA), on a sequencer ABI 3130XL (16-
capillaries).
The PCR product purification method was used in
order to confirm sequencing by reverse primer. The PCR
products were purified using QIAquick PCR purification
Kit (50) (QIAGEN, USA).
Statistical analysis
χ2 testing was employed to assess the influence of poly-
morphism status on features of breast cancer. Uncondi-
tional logistic regression analysis was performed using
SPSS software (version 11.5 for Windows XP; SPSS Inc.,
Cary, NC, USA) to calculate odds ratios (ORs) with 95%
confidence intervals (CIs) and to examine the predictive
effect of each factor on risk for breast cancer. P < 0.05 was
considered as statistically significant.
Results
In this study, 150 breast cancer patients and 147 healthy
women without family history of breast cancer were
selected as controls. In exon #3, we did not find novel
mutation or any synonymous SNP in the Iranian popula-
tion. Exon #7 revealed no novel mutations but a silent
SNP in codon 392 (Leu 392 Leu), rs1256054
(dbSNP128), a conversion of nucleotide C to G (C 1176
G) was observed. Both CTC and CTG code for Leucine
amino acid. The observed numbers of individuals with
different genotypes showed that this SNP fitted the
Hardy-Weinberg equilibrium for both control and patient
groups (P  > 0.05). The codon 392 polymorphism was
found only in patients. Statistically significant frequency
was achieved; 8.7% for the CG genotype, and 1.3% for the
GG genotype in comparison to 90.0% CC in the normal
genotype (χ2 = 4.769, P = 0.029) (Table 2).
Among all risk factors, only race and ABO blood
groups were statistically significant (P< 0.05) between
cases and controls. Women from the Fars province (near
the southern part of Iran) revealed a significant genotypic
distribution frequency only within CG heterozygote
patients (χ2 = 9.11, P  = 0.003). When the ABO blood
groups were considered, A and B blood groups showedAbbasi BMC Medical Genetics 2010, 11:109
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statistically significant frequencies between cases and
controls (χ2 = 4.920, P = 0.027, and χ2 = 5.108, P = 0.024
respectively) (Table 3).
Among breast cancer patients, 70.1% revealed a first-
degree family history of breast cancer with CG (52.6%) or
GG (10.5%) genotype and 2.3% without family history of
breast cancer with CG genotype. This difference was sta-
tistically significant (χ2 = 27.645, P = 0.001). In breast can-
cer patients with LN metastasis, the genotypic
distribution frequency of codon 392 showed statistically
significant difference with frequencies of 30.4% for CG
and 8.7% for GG, in comparison with breast cancer
patients without LN metastases (4.7%) (χ2 = 17.314, P =
0.001) (Table 4).
The frequency of allele 392G was significantly (χ2=
4.583, P = 0.032) higher in cancer patients with the age at
menarche being 12 years old or below (9.2%) than those
reaching menarche above 12 years of age (3.3%). The fre-
quency of allele 392G was significantly higher in cancer
patients with a first-degree family history (36.8%) than in
those without a family history (1.1%, with a difference of
35.7%), in comparison with the frequency of allele 392C
which is significantly lower in cancer patients with a first-
degree family history than in those without a family his-
tory (χ2 = 78.847, P  = 0.001) (Table 5). Moreover, the
allelic frequency of 392C was significantly higher in can-
cer patients with LN metastases (23.9%) than in those
without LN metastases (2.4%) with a difference of 21.5%,
in comparison with the frequency of allele 392 C which
was significantly lower in cancer patients with LN metas-
tases (76.1%) than in those without LN metastases
(97.6%) (χ2 = 33.838, P = 0.001) (Table 5).
Significant correlation was found for first-degree rela-
tives with family history of breast cancer and LN metas-
tasis, as indicated by the ORs presented in Table 6. In
regards to the criterion of breast cancer, genotype fre-
quencies exhibited a significantly different distribution in
cases and controls (P = 0.029). The estimated risk was
higher in cases (47.9%) than in controls (52.1%) in indi-
viduals with the normal CC, genotype. Nevertheless, CG
or GG genotype in codon 392 was observed only in breast
cancer patients.
Furthermore, genotype frequencies exhibited different
distributions in the presence or absence of a first-degree
relative family history of breast cancer, with statistical sig-
nificance for codon 392 (P = 0.001) and LN metastasis.
The estimated risk was very much lower for both CG
individuals with family history of breast cancer LN
metastasis than controls (OR 0.016 and 0099 respectively,
95% CI). Moreover, GG genotype was only observed in
individuals with family history of breast cancer and LN
metastasis (Table 6).
Discussion
ER-β is one of the most important players in the mecha-
nism of estrogen action and is found in many tissues,
including the central nervous system, cardiovascular sys-
tem, immune system, urogenital tract, gastrointestinal
tract, kidneys and lungs. It is an obvious candidate gene
to harbor allelic variants which predispose to breast can-
Table 1: Primers selected for Exons #3 and #7 of Gene ER-β
Polymorphism site Melting temperature (°C) Oligonucleotic sequences Sequence size
Exon 3 59.23
59.86






Primers for PCR reaction
F 5' GATGAGGGGAAATGCGTAGA 3'
R 5' GGCCCAGCTGTGTGATTACT 3'
156
Table 2: Genotypic distribution frequencies of codon 392 in exon 7 of estrogen receptor-β gene in the study population: 
breast caner versus control groups
Codon 392 Normala Heterozygoteb Homozygotec Total Test result
Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Case 135 90.0 13 8.7 2 1.3 150 100 χ2 = 4.769
P = 0.029
Control 147 100 - - - - 147 100
Total 282 94.9 13 4.4 2 0.7 297 100
a Genotype normal or 329CC, CTC/CTC, b Genotype heterozygote or 329CG, CTC/CTG, c Genotype homozygote or 329GG, CTG/CTGAbbasi BMC Medical Genetics 2010, 11:109
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Table 3: Genotypic distribution frequencies of codon 392 in exon 7 of estrogen receptor-β gene and major risk factors in 
study population: breast cancers, versus control groups
Characteristic Group 00a %0 1 b %1 1 c % Test result
Age at menarche(years)
</= 12 Case 83.3 15.0 1.7 χ2 = 1.887
P = 0.169
control 100 - -
total 89.6 9.4 1.0
> 12 Case 94.4 4.4 1.1 χ2 = 2.229
P = 0.135
control 100 - -
total 97.5 2.0 0.5
Race
Arab & Armani Case 100 - - -
control - - -
total 100 - -
Fars Case 90.0 10.0 - χ2 = 9.11
P = 0.003
control 100 - -
total 95.9 4.1 -
Lor & Kurdish Case 83.3 11.1 5.6 χ2 = 0.697
P = 0.404
control 100 - -
total 88.9 7.4 3.7
Turkish Case 93.5 4.3 2.2 χ2 = 1.17
P = 0.279
control 100 - -
total 96.5 2.4 1.1
Gilaki & Mazani Case 87.0 13.0 - χ2 = 1.527
P = 0.217
control 100 - -
total 91.2 8.8 -
ABO blood Groups
A Case 88.9 11.1 - χ2 = 4.920
P = 0.027
control 100 - -
total 95.7 4.3 -
B Case 85.7 14.3 - χ2 = 5.106
P = 0.024
control 100 - -
total 95.9 4.1 -
AB Case 100 - - -
control 100 - -
total 100 - -
OC a s e 9 0 . 3 7 . 8 1 . 9 χ2 = 1.884
P = 0.17
control 100 - -
total 93.6 5.1 1.3
a Genotype normal or 329CC, CTC/CTC, b Genotype heterozygote or 329CG, CTC/CTG, Genotype homozygote or 329GG, CTG/CTGAbbasi BMC Medical Genetics 2010, 11:109
http://www.biomedcentral.com/1471-2350/11/109
Page 5 of 9
cer [35]. There are several studies examining the associa-
tion of ER-β variants and breast cancer risk in different
populations [26-33], but these studies do not include
rs1256054, with the exception to Zheng et al. [29]. This
is the first study focusing on genetic variations of the ER-
β gene in breast cancer patients in Iran. Two single nucle-
o t i d e  p o l y m o r p h i s m s  i n  t h e  E R - α  g e n e  i n  r e l a t i o n  t o
breast cancer were studied before [24,40]. In the present
study, the SNPs are detected only in the cancer patient
group, with significant (P = 0.029) increase of CG geno-
type (8.7%) as compared with the GG genotype (1.3%),
suggesting the CG genotype confers risk for development
of breast cancer (Table 2). Furthermore, the frequency of
the CG genotype was found to be significantly (P < 0.005)
increased in the Fars race and also in both blood groups
A and B in comparison with the other risk factors (10%,
11.1% and 14.3% respectively) indicating that both CG
genotype and mentioned characteristics might have
influence in developing breast cancer (Table 3). SNPs in
different regions of the ER-β gene previously reported
suggest the associate of ER-β polymorphisms with breast
cancer, anorexia nervosa, Parkinson and ovulatory dys-
function [26-28,36-39].
Increased frequency of CG genotype was also observed
in patients with first-degree relative family history of
breast cancer as compared to patients with no family his-
tory of breast cancer (a difference of 50.3%) in compare
with GG genotype (a difference of 10.5%) suggesting that
CG genotype might influence development of familial
breast cancer more than the GG genotype. When LN sta-
Table 4: Genotypic distribution frequencies of codon 392 in exon 7 of estrogen receptor-β gene and selected 
demographic characteristics and major risk factors
Characteristic 002 %0 1 b%1 1 c %T e s t  r e s u l t
BMI (kg/m2)
</= 18.5 80.0 20.0 - χ2 = 0.144
P = 0.705
18.5-24.9 91.2 7.0 1.8
25-29.9 90.9 9.1 -
> 30 87.9 9.1 3.0
Total 90.0 8.7 1.3
Onset age of breast cancer (years)
</= 40 91.7 8.3 - χ2 = 0.959
P = 0.328
> 40 89.2 8.8 2.0
Total 90.0 8.7 1.3
Family history of breast cancer
First-degree family affected 36.8 52.6 10.5 χ2 = 27.645
P = 0.001
Not affected 97.7 2.3 -
Total 90 8.7 1.3
Lymph node metastases
Yes 60.9 30.4 8.7 χ2 = 17.314
P = 0.001
No 95.3 4.7 -
Total 90.0 8.7 1.3
ER expression in breast cancer tissue
Positive 80.0 15.0 5.0 χ2 = 4.799
P = 0.028
Negative 94.6 5.4 -
Not studied 88.9 11.1 -
Total 90.0 8.7 1.3
a Genotype normal or 329CC, CTC/CTC, b Genotype heterozygote or 329CG, CTC/CTG, c Genotype homozygote or 329GG, CTG/CTGAbbasi BMC Medical Genetics 2010, 11:109
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Table 5: Allelic frequencies of estrogen receptor-β exon 7, codon 392 (CTC/CTG) in the study population: breast cancer 




Case (n = 150) 283(94.3%) 17(5.7%)
Control (n = 147) 294(100%) -
χ2 = 17.122, P = 0.001
Age at menarche(years)
</= 12 (n = 60) 109(90.8%) 11(9.2%)
> 12 (n = 90) 174(96.7%) 6(3.3%)
χ2 = 4.583, P = 0.032
Age at menopause (years)
=< 50 (n = 47) 87(92.6%) 7(7.4%)
> 50 (n = 12) 24(100%) -
χ2 = 1.884, P = 0.17
ABO blood groups
A (n = 27) 51(94.4%) 3(5.6%)
B (n = 14) 26(92.9%) 2(7.1%)
AB (n = 6) 12(100%) -
O (n = 103) 194(94.2%) 12(5.8%)
χ2 = 0.058, P = 0.81
Race
Arab & Armani (n = 3) 6(100%) -
Fars (n = 60) 114(95.0%) 6(5.0%)
Lor & Kurdish (n = 18) 32(88.9%) 4(11.1%)
Turkish (n = 46) 88(95.7%) 4(4.3%)
Gilaki & Mazani (n = 23) 43(93.5%) 3(6.5%)
χ2 = 0.05, P = 0.822
Family history of breast cancer
First-degree family affected (n = 19) 24(63.2%) 14(36.8%)
Not affected (n = 131) 259(98.9%) 3(1.1%)
χ2 = 78.847, P = 0.001
Lymph node metastases
Yes (n = 23) 35(76.1%) 11(23.9%)
No (n = 127) 248(97.6%) 6(2.4%)
χ2 = 33.838, P = 0.001
ER expression in breast cancer tissue
Positive (n = 40) 70(87.5%) 10(12.5%)
Negative (n = 92) 179(97.3%) 5(2.7%)
Not studied (n = 18) 34(94.4%) 2(5.6%)
χ2 = 5.161, P = 0.023
a Allele 392C, CTC, b Allele 392G, CTGAbbasi BMC Medical Genetics 2010, 11:109
http://www.biomedcentral.com/1471-2350/11/109
Page 7 of 9
tus of the patients were considered again, the frequency
of CG genotype was 21.7% greater in patients with LN
metastasis than those without LN metastasis in compari-
son with the frequency of GG genotype (a difference of
8.7%), indicating that CG genotype might associate with
LN metastasis in Iranian population (Table 4).
Some studies such as investigations conducted in
Shanghai [29], Sweden [30] and the US [31] found no
overall statistically significant differences between the
allelic frequencies of cases and controls. However, a num-
ber of investigations conducted in different populations
such as Finland [32], India [26], Germany [33] and Japan
[37] have found a statistically significant difference
between the allelic frequencies of cases and controls as
we found here in our study. The results strengthened the
association between codon 392 polymorphism and breast
cancer development. Furthermore, we found allelic fre-
quency of G to be significantly much higher in cases with
the history of breast cancer in first-degree relatives when
compared with non-familial cases (with difference of
35.7%). An increased frequency of allele G was also
observed in patient with LN metastasis as compared with
patients without LN metastasis (with differences of
21.5%)(P  = 0.001) which suggest that the presence of
allele G might be predictive of both familial breast cancer
and bad progression of the disease (Table 5). In terms of
practical utility, the relation between codon 392 variant
and probability of LN metastasis deserves further consid-
eration as a clinical indicator during pre-surgical evalua-
tion. Such a test is of interest because lymphatic invasion
is associated with local recurrence and disease progres-
sion, and LN metastasis is considered an important indi-
cator when deciding whether chemotherapy should be
given [41-44].
Nevertheless, the link between silent polymorphisms
and phenotypes is unclear. One of the possibilities might
be that the silent polymorphism is in linkage with another
genetic mutation that directly affects breast cancer phe-
notype. The other possibility might be that the nucleotide
composition at the silent polymorphic site could alter the
gene expression level of ER-β, thus leading to LN metas-
tasis in breast cancer.
Table 6: Estimated risk for selected demographic characteristic and major risk factors with estrogen receptor-β exon 7, 
codon 392 in different genotypes
Breast cancer Yes No P value OR (95% CI)
Genotype n = 150 n = 147
Normala 135(47.9%) 147(52.1%) 0.029 1.0(reference)
Heterozygoteb 13(100%) - -
Homozygotec 2(100%) - -
Age at menarche (years) </= 12 > 12 P value OR (95% CI)
Genotype n = 60 n = 90
Normal 50(37.0%) 85(63%) 0.437 1.0(reference)
Heterozygote 9(69.2%) 4(30.8%) 0.261(0.077-0.893)
Homozygote 1(50%) 1(50%) 0.588(0.036 -9.613)
First- degree family history of breast cancer Affected Not affected P value OR (95% CI)
Genotype n = 19 n = 131
Normal 7(5.2%) 128(94.8%) 0.001 1.0(reference)
Heterozygote 10(76.9%) 3(23.1%) 0.016(0.004- 0.073)
Homozygote 2(100%) - -
Lymph node metastases Yes No P value OR (95% CI)
Genotype n = 23 n = 127
Normal 14(10.4%) 121(89.6%) 0.001 1.0(reference)
Heterozygote 7(53.8%) 6(46.2%) 0.099(0.029 - 0.337)
Homozygote 2(100%) - -
a Genotype normal or 329CC, CTC/CTC, b Genotype heterozygote or 329CG, CTC/CTG, c Genotype homozygote or 329GG, CTG/CTGAbbasi BMC Medical Genetics 2010, 11:109
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ER-β genotypes were compared with selected clinical
breast cancer features, including age at menarche, family
history of breast cancer, and LN metastasis. Significant
correlation (P = 0.001) was found for family history of
breast cancer and LN metastasis, as indicated by the ORs
presented in Table 6. The estimated risk was much lower
for individuals with family history of breast cancer and
patients with LN metastasis who were heterozygote in
codon 392 (OR 0.016 and OR 0.099 respectively with 95%
CI) than for the corresponding controls. This indicates
that codon 392 polymorphism does not influence breast
cancer risk
Taken together, codon 392 SNP might influence devel-
opment of familial breast cancer and LN metastasis but it
cannot be considered as a breast cancer risk factor.
Conclusion
We have identified codon 392 CTC/CTG polymorphism
to be associated with an increased risk of familial breast
cancer with LN metastasis. Moreover, CG heterozygosity
increases in familial breast cancer and LN metastasis.
However, our results imply that although the SNP exam-
ined in this study does not play a causal role in the etiol-
ogy of breast cancer, the ER-β gene variants may be
involved in breast cancer susceptibility. This was the first
systematic association study in ER-β variants with vari-
ous aspects of breast cancer in Iran. ER-β genotype, as
determined during pre-surgical evaluation, might present
a surrogate marker for predicting breast cancer lymph
node metastasis. Further analysis is needed to elucidate
the role of ER-β polymorphisms in breast cancer suscep-
tibility. Continuation of this study on other regions of the
ER-β gene will provide additional insight into the biology
and complex etiology of breast carcinogenesis.
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